HCV-1: first-line triple-DAA short course shows efficacy

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • A triple combination of direct-acting antivirals (DAAs) consisting of simeprevir (SMV) with sofosbuvir (SOF) and daclatasvir (DCV) offers an effective short-course first-line treatment option for patients with HCV-1 and early fibrosis or compensated cirrhosis.

Why this matters...